RxDoctor Payments Data

Jeffrey Howe, MD

Family Medicine · Elkhart, INNPI 1750380424

Payments from drug & device makers

$341in general payments, 2019–2025

Across 20 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$68
  • AbbVie$35
  • GSK$32
  • Pfizer$30
  • Biohaven Pharmaceutical Holding Company Ltd.$26
  • Abbott$23
  • plus $127 from 7 others

What the payments were for

  • Food & beverage$27882%
  • Education$6218%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$341 in reported general payments places this provider in the 40th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$270,445
Medicare patients
648
Services billed
15,497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide172$199,680
OzempicSemaglutide115$130,896
Trelegy ElliptaFluticasone/Umeclidin/Vilanter142$127,733
TrulicityDulaglutide67$111,052
JardianceEmpagliflozin69$87,192
EliquisApixaban57$72,406
XareltoRivaroxaban27$36,836
FarxigaDapagliflozin Propanediol28$32,758
MyrbetriqMirabegron29$24,203
JanuviaSitagliptin Phosphate18$23,644
JanumetSitagliptin Phos/Metformin Hcl25$23,182
Lantus SolostarInsulin Glargine,hum.Rec.Anlog118$22,740
GemtesaVibegron28$21,001
Breo ElliptaFluticasone/Vilanterol33$18,481
Stiolto RespimatTiotropium Br/Olodaterol Hcl28$15,196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Lyumjev$12$321,835250 claims
GSKTrelegy Ellipta, Breo Ellipta$32$146,214175 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta, Jentadueto$19$128,130125 claims
PfizerEliquis$30$72,40657 claims
AstraZenecaFarxiga, Symbicort$12$41,27842 claims
AbbVieSynthroid$35$6,110119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Elkhart

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →